Dynavax Technologies Corp. (NASDAQ:DVAX) rose 3.6% during mid-day trading on Thursday . The company traded as high as $16.21 and last traded at $16.20, with a volume of 240,590 shares trading hands. The stock had previously closed at $15.63.

DVAX has been the topic of a number of recent research reports. Zacks Investment Research upgraded Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a research note on Wednesday, May 25th. JPMorgan Chase & Co. cut shares of Dynavax Technologies Corp. from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $29.00 to $22.00 in a research note on Wednesday, April 27th. Cowen and Company restated a “buy” rating and set a $60.00 price objective on shares of Dynavax Technologies Corp. in a research note on Thursday, April 28th. Finally, Royal Bank Of Canada cut shares of Dynavax Technologies Corp. from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $48.00 to $17.00 in a research note on Wednesday, April 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. Dynavax Technologies Corp. currently has a consensus rating of “Hold” and a consensus price target of $32.20.

The stock has a 50-day moving average price of $15.37 and a 200-day moving average price of $17.10. The stock’s market cap is $622.11 million.

Dynavax Technologies Corp. (NASDAQ:DVAX) last released its quarterly earnings data on Friday, August 5th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by $0.07. The firm earned $2.65 million during the quarter, compared to analyst estimates of $1.58 million. The company’s revenue for the quarter was up 70.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.80) EPS. On average, equities research analysts anticipate that Dynavax Technologies Corp. will post ($2.96) EPS for the current year.

In other news, CEO Eddie Gray acquired 2,750 shares of the stock in a transaction dated Friday, May 20th. The shares were acquired at an average cost of $15.57 per share, for a total transaction of $42,817.50. Following the completion of the transaction, the chief executive officer now owns 5,050 shares in the company, valued at approximately $78,628.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

A hedge fund recently raised its stake in Dynavax Technologies Corp. stock. Swiss National Bank increased its position in shares of Dynavax Technologies Corp. (NASDAQ:DVAX) by 5.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 48,528 shares of the biopharmaceutical company’s stock after buying an additional 2,600 shares during the period. Swiss National Bank owned approximately 0.13% of Dynavax Technologies Corp. worth $1,172,000 as of its most recent SEC filing.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.